1. LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness.
- Author
-
Pallavicini, Isabella, Frasconi, Teresa Maria, Catozzi, Carlotta, Ceccacci, Elena, Tiberti, Silvia, Haas, Dorothee, Samson, Jule, Heuser-Loy, Christoph, Nava Lauson, Carina B., Mangione, Marta, Preto, Elisa, Bigogno, Alberto, Sala, Eleonora, Iannacone, Matteo, Mercurio, Ciro, Gattinoni, Luca, Caruana, Ignazio, Kuka, Mirela, Nezi, Luigi, and Minucci, Saverio
- Abstract
The lysine-specific histone demethylase 1 A (LSD1) is involved in antitumor immunity; however, its role in shaping CD8 + T cell (CTL) differentiation and function remains largely unexplored. Here, we show that pharmacological inhibition of LSD1 (LSD1i) in CTL in the context of adoptive T cell therapy (ACT) elicits phenotypic and functional alterations, resulting in a robust antitumor immunity in preclinical models in female mice. In addition, the combination of anti-PDL1 treatment with LSD1i-based ACT eradicates the tumor and leads to long-lasting tumor-free survival in a melanoma model, complementing the limited efficacy of the immune or epigenetic therapy alone. Collectively, these results demonstrate that LSD1 modulation improves antitumoral responses generated by ACT and anti-PDL1 therapy, providing the foundation for their clinical evaluation.The lysine-specific histone demethylase 1 A (LSD1) can regulate cytotoxic CD8 T cell (CTL) responses and anti-tumor immunity. Here the authors show that ex vivo epigenetic reprogramming with a LSD1 inhibitor enhances cell persistence and anti-tumor activity of adoptively transferred CD8 T cells in preclinical tumor models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF